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Abstract 
Background Vascular alterations are significant events in the pathomechanism of psoriasis. A disorder in the 
mechanisms regulating skin angiogenesis and lymphangiogenesis could participate in the pathogenesis of the 
disease.  
Objectives To quantify differences in the expression of angiogenesis and lymphangiogenesis growth factors, 
receptors, coreceptors as well as their antagonists in the uninvolved skin of patients with psoriasis compared with 
the skin of non-psoriatic volunteers. 
Methods Skin biopsies were collected from the involved skin of 13 patients with untreated plaque-type psoriasis, 
from their nonlesional skin at distance from the lesions and from the skin of 16 healthy volunteers. The mRNA 
steady-state level of keratins 10, 14 and 16, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), vimentin, 
collagen I and IV, proliferating cell nuclear antigen, the various splice variants of vascular endothelial growth 
factor, VEGF-A, VEGF-C and VEGF-D, their receptors VEGFR1, VEGFR2 and VEGFR3, neuropilin (NRP)-1 
and its soluble forms, NRP-2, semaphorin 3A and prox-1, was measured by reverse transcription—polymerase 
chain reaction. Immunohistochemistry was performed for Ki-67, von Willebrand factor and D2-40. Blood and 
lymphatic vessel density, area and distance from epidermis were estimated by morphological analysis coupled to 
an original computer-assisted method of quantification.  
Results Skin from healthy volunteers and nonlesional skin from patients with psoriasis displayed similar 
histological, morphometric and proliferative features. However, a significant overexpression of VEGFR3, the 
VEGF-A isoform VEGF121, soluble 12 NRP-1 and GAPDH was observed in the nonlesional psoriatic skin as 
compared with that of normal volunteers. 
Conclusions These data point to significant differences in the blood and lymphatic vascular transcriptome 
between the clinically normal-appearing skin of patients with psoriasis and the skin of volunteers without 
psoriasis. 
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The development of psoriasis lesions depends on multiple interactions between susceptibility genes and 
environmental factors. The pathogenesis of psoriasis includes epidermal hyperplasia, impaired epidermal 
differentiation, accumulation of inflammatory cells and excessive angiogenesis with enlarged, tortuous and 
hyperpermeable dermal blood vessels.
2 
Vascular expansion is an early event that precedes epidermal changes
3,4
 
and persists after recession of the epithelial and inflammatory alterations
5
. This has led to the suggestion that 
psoriasis is an angiogenesis-dependent disease. 
Both angiogenesis and lymphangiogenesis are complex multistep processes and the delicate balance between the 
numerous positively and negatively acting mediators leads to expansion or recession of the vascular network
6
. 
The vascular endothelial growth factor (VEGF) family plays a significant role in these processes. VEGF-A, that 
induces vascular endothelial cell proliferation and increased permeability, binds to two related tyrosine kinase 
receptors, VEGFR1 and VEGFR2, the latter being the major signalling mediator of the  angiogenic  effects.   
VEGF-A is overexpressed in the psoriatic epidermis and increases the expression of VEGFR2 in endothelial 
cells
7
. Alternative splicing of its gene generates at least six molecular variants. VEGF165 and the freely 
diffusible VEGF121 are the major isoforms. VEGF189, VEGF206 and, to a lesser extent, VEGF165 are 
associated to the extracellular matrix and are released upon proteolysis
8
. We recently described a new isoform, 
VEGF111, induced by genotoxic agents, biologically active and resistant to proteolysis.
9
 Placental growth factor 
(PlGF), another key mediator of skin angiogenesis that is upregulated during hair follicle cycle and wound 
healing
10
, may directly stimulate VEGFR1 and potentiate VEGF activity. Alternative exon splicing generates 
four different isoforms, PlGF-1-PlGF4,
11,12
 with different binding affinities to heparin and neuropilins, PlGF-2 
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During the last decade, the lymphatic system has been the subject of increasing interest with the discovery of 
specific factors among which are the lymphatic growth factors VEGF-C and VEGF-D
13
. Their tyrosine kinase 
receptor VEGFR3 found in venous and lymphatic endothelial cells during embryogenesis becomes restricted to 
lymphatic cells early in the postnatal period except for the fenestrated blood vessels of some organs such as 
endocrine glands.
14
 The activation of VEGFR3 by VEGF-C or VEGF-D leads to proliferation of the lymphatic 
endothelial cells while targeted deletion of VEGF-C in mice impairs the development of small lymphatic 
vessels.
13
 Lymphatics are expanded in psoriasis but little is known about the mechanism of their development in 
the lesions and potential alterations in the noninvolved skin of the patients. 
Differences between the uninvolved skin of patients with psoriasis and the skin of healthy individuals have been 
documented, such as increased expression of keratin 16
15
 and phosphorylated NF-κB/RelA,16 reduced keratin 15 
and β1 integrin expression17, or papillary oedema and endothelial cells swelling during psoriasis flares18. 
Vascular volume
19
 and adhesion receptors such as intercellular adhesion molecule-1 and E-selectin
20
 have been 
reported to be increased in the nonlesional psoriatic skin. These observations suggest the existence of a 
prepsoriatic phenotype in the distant nonlesional skin, but little is known about their potential significance in the 
pathomechanisms of the disease. 
The aim of our study was to evaluate by reverse transcription-polymerase chain reaction (RT-PCR) and 
immunohistochemistry the expression of angiogenesis and lymphangiogenesis markers to search for potential 
differences between the normal-appearing skin in psoriasis and the skin of healthy volunteers. These markers 
were also evaluated in the psoriatic lesions of the same patients. Our study provides evidence that the distant 
uninvolved skin in psoriasis displays vascular and lymphatic transcriptomic differences when compared with 
healthy skin without major modification in the expression of epidermal or dermal genes or morphological 
alterations. 
MATERIALS AND METHODS 
Patients 
Thirteen adult patients (eight women and five men) with moderate to severe plaque-type psoriasis (Psoriasis 
Area and Severity Index median score 8
.
5) who had not received any systemic treatment for 1 month or any 
topical therapy for 2 weeks underwent skin punch biopsy (4 mm) after local anaesthesia (1% xylocaine with 
adrenaline) in a lesion and in the distant uninvolved skin (at least 2 cm from the nearest plaque). Sixteen 
volunteers (six women and 10 men) who had no personal or familial history of psoriasis were also biopsied. The 
mean ± SD age was 37 ± 14 years (range 21-67) and 45 ± 19 years (range 21-76) for the psoriasis and volunteers 
group, respectively. Biopsies were snap frozen in liquid nitrogen and stored at -80°C until use. Biopsies from 15 
additional untreated patients and 11 other volunteers were embedded in paraffin after fixation in 3% formalin or 
in OCT. This study was approved by the Ethics Committee of the University Hospital of Liège. The patients 
gave their written informed consent to participate in the study and the Declaration of Helsinki protocols were 
followed. 
RNA isolation and reverse transcription-polymerase chain reaction 
Total RNA was purified (High Pure RNA Tissue kit; Roche Molecular Biochemicals, Mannheim, Germany) 
from the frozen biopsies after crushing in liquid nitrogen (Dismembrator Braun Technology International, 
Melsungen, Germany), and quantified (RiboGreen, R-11491; Molecular Probes, Invitrogen, Merelbeke, 
Belgium). The RT-PCR amplifications were performed in an automated thermal cycler (GeneAmp PCR System 
9700 using a GeneAmp thermostable rTth Reverse Transcriptase RNA PCR kit; Applied Biosystems, Foster 
City, CA, U.S.A.) with pairs of primers described in previous publications
21-25
. For RT-PCR amplification of 
PlGF, forward and reverse primers were chosen in regions surrounding the alternatively skipped sequences, 
allowing the discrimination the four isoforms on an electrophoretic mobility basis. A comparable strategy was 
used for VEGF-A.
9,26
 For quantitative RT-PCR measurements, 3 ng of total RNA was used per 20 µL reaction 
mixture. The efficiency of the RT and the PCR reactions for 28S, glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH), collagen I, VEGF-A and semaphorin 3A was controlled by a synthetic RNA.
23-25
 The amplification 
products were separated by polyacrylamide gel electrophoresis, stained (Gelstar, Cambrex, Rockland, ME, 
U.S.A.), and quantified (Fluor-S Multilmager; Biorad, Hercules, CA, U.S.A.). The results of quantification 
expressed in arbitrary units [per unit of 28S ribosomal RNA (28S rRNA)] are given as the mean ± SD percentage 
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of the values measured in skin from healthy volunteers taken as 100%. 
RNA was extracted from several 50-µm sections from 10 OCT-embedded biopsies of each lesion category and 
the surface of each biopsy was measured. RT-PCR was performed to measure 28S rRNA and VEGF-A, 
VEGFR2 and VEGFR3 mRNA, using a Superscript II Reverse Transcriptase (Invitrogen) and a Takara Taq 
polymerase (Biomedical Group, Shiga, Japan). The mRNA level was calculated by unit volume of tissue. 
Histology 
Five-micrometre serial paraffin sections were stained with antihuman Ki-67 (Clone MIB-1; DakoCytomation, 
Glostrup, Denmark), antihuman von Willebrand factor (DakoCytomation) and anti D2-40 (Proteogenix, Illkirch, 
France). Secondary antibodies coupled to peroxidase were used for Ki-67 and von Willebrand factor (goat 
antimouse Envision and swine antirabbit, respectively; DakoCytomation). For D2-40, a goat antimouse antibody 
coupled to biotin was used, followed by incubation with streptavidin coupled to peroxidase (both from 
DakoCytomation). Peroxidase activity was revealed with diaminobenzidine for Ki-67 and with 3-amino-9-
ethylcarbazole for D2-40 and von Willebrand immunohistochemistry. 
Image analysis 
Visual image quantification 
Epidermal and dermal cellularity was evaluated by counting the number of cells per high power field in 5-µm 
sections of seven samples of uninvolved psoriatic skin and seven samples of healthy skin. The acanthosis score, 
evaluated by the ratio between epidermal area and horny layer length, and papillomatosis score, evaluated by the 
ratio between basement membrane and horny layer lengths, were calculated for each group of biopsies on 5-µm 
haematoxylin and eosin-stained sections (Axiovert 25 Zeiss equipped with a CCD camera and KS 400 software; 
Carl Zeiss Vision GmbH, Aalen, Germany). The Ki-67 labelling index was expressed as the number of positive 
cells as a percentage of the total basal and suprabasal cells. A minimum of 300 cells was counted on × 40 
magnification photographs for each specimen. 
Semiautomatic image quantification 
Images of sections were observed and digitized with the Axiovert 25 Zeiss microscope coupled to a CCD camera 
(Carl Zeiss Vision GmbH). An original algorithm for image processing and measurements was implemented 
with the Aphelion 3.2i software (Adcis, Hérouville Saint-Clair, France) as detailed in Figure 1. The following 
parameters were measured: (i) the mean size of vessels, (ii) the mean distance of vessels to the basal membrane 
and (iii) the mean density of vessels per area of superficial dermis (dermis between the superficial vascular 
plexus and the dermoepidermal basement membrane). 
Statistical evaluation 
Results are expressed as mean ± SD. Statistical analysis was performed using ANOVA and Scheffé's test to 
compare the three groups and the paired Student's t-test to compare the non-lesional and lesional skin in the 
psoriasis group. Student's t-tests were applied to compare the histological parameters between the groups. To 
normalize the distribution, a log transformation was applied for some variables. Discriminant analysis was 
performed to identify variables enabling discrimination between the three groups. Results were considered to be 
significant at the 5% confidence level (P < 0.05). Within each group, Pearson correlation coefficients were 
calculated between each pair of variables. Calculations were done using the SAS software (version 9.1 for 
Windows) (SAS Institute, Cary, NC, U.S.A.). 
RESULTS 
Morphological parameters 
No difference was observed between nonlesional psoriatic and healthy volunteer skin in terms of cellularity, 
proliferating rate, papillomatosis or acanthosis indexes (Fig. 2). As expected, these parameters were significantly 
increased in the psoriatic lesions. The density of blood and lymphatic vessels in the superficial dermis as well as 
their surface area were similar in the uninvolved skin from patients with psoriasis and skin from healthy 
volunteers but were largely increased in the lesions of psoriasis. The mean distance of lymphatic vessels to the 
basement membrane was comparable in the normal skin from both psoriasis and volunteers, but lymphatic 
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capillaries were significantly closer to epidermis in the psoriatic lesions. Such a pattern was not observed for 
blood vessels, which were at similar distance from the basement membrane in the three groups. 
 
Fig 1: Illustration of the image analysis algorithm used to quantify the density, the size and the distance to the 
basal membrane of lymphatic and blood vessels. (a) A typical D2-40-stained section in which lymphatic vessels (as well as part 
of the basal keratinocyte layer) can be distinguished by a brownish colour. After splitting the colour image to its grey level components, 
vessels were better contrasted in the green component (c) than in the red (b) or blue one (d). Vessels were segmented automatically using the 
entropy of histogram of grey level intensities    and geodesic transformations were used to eliminate the vessels placed in the border of the 
image and to fill their lumen. Finally, an erosion filter was used to eliminate small artefacts, and the resulting image is used as marker to 
reconstruct the final binary image (e). The manually drawn contour of the region located between the basement membrane and the superficial 
vascular plexus (f) was binarized and the area filled automatically (g). The application of this mask on the segmented image of vessels (e) 
allowed us to obtain an image containing only those vessels placed between the superficial vascular plexus and the basement membrane (h). 
Then, each vessel was individualized by a colour (labelled image, i) in order to measure its corresponding area. The mean distance between 
vessels and the basement membrane was calculated as follows. The distance transformation43 was applied to the binary image of the mask. In 
the resulting grey level image (k), the intensity associated to each pixel is the Euclidean distance to the nearest 'black' point, i.e. the nearest 
external border of the basement membrane. Then, the grey level intensities of the image obtained intersecting the image containing the centre 
of gravity of each vessel and the image distance of the mask (k) are the nearest distances from each vessel to the basal membrane. For the 
sake of clarity, (1) shows the intersection of the image distance (k) with the image of vessels (i), rather than with the image of their centres of 
gravity. 
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Fig 2: Immunostaining of cycling cells, blood and lymphatic vessels in nonpsoriatic skin (NV), uninvolved 
psoriatic skin (NP) and lesional psoriasis (LP). Paraffin-embedded sections were stained with antihuman von Willebrand factor 
(vW) (blood vessels), D2-40 (lymphatic vessels) and Ki-67 (cycling cells). Serial sections of LP were stained with D2-40 and vW. 
Cellularity was counted in epidermis and superficial dermis of the skin of seven healthy volunteers and seven patients (uninvolved skin) on 
haematoxylin and eosin-stained sections. Papillomatosis and acanthosis scores were evaluated for all the patients. The Ki-67 labelling index 
was expressed as the number of positive cells as a percentage of the total basal and suprabasal cells. Blood and lymphatic vessel sections 
were measured using computerized image analysis. A quantification of the morphological observations is given below the figure. Scale bar = 
100 µm. 
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3 ± 005 2 ± 002
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Ki-67 22 ± 6% 25 ± 5% 50 ± 9%
8
            
1Mean ± SD; 2not determined; 3ratio between basement membrane and horny layer length; 4ratio between epidermal area and horny layer 
length; 5distance to basement membrane; 6mean area of vessels; 7area of vessels in % of area of superficial dermis; 8statistically significant 
(P< 0.05) difference when compared to NP and NV; 9Statistically significant (P< 0.05) difference when compared to NP. 
 
Critical analysis of the reverse transcription-polymerase chain reaction procedure to measure the mRNA 
of selected genes 
The type of information used for quantifying the expression of representative gene products in the present study 
is illustrated in Figure 3. The results were expressed as arbitrary units of a specific mRNA per unit of 28S rRNA. 
This calculation is adequate for the comparison between nonlesional skin in psoriasis and skin from healthy 
volunteers, as cellularity is similar in the epidermal and dermal compartments as shown in Figure 2. As the 
psoriatic lesions contain a large excess of epithelial and inflammatory cells, a significant proportion of RNA 
collected in the lesional skin is of epithelial and inflammatory origin and dilutes the RNA originating from the 
less abundant dermal cells. The 28S rRNA collected from cryostat sections, calculated per unit volume of tissue, 
was indeed 3
.
5 times higher in the lesions than in the distant unaltered skin (data not shown). We therefore did 
not evaluate the statistical significance of the differences between lesional and nonlesional skin in Table 1. The 
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mRNA level values reported for the lesional skin were used only to identify angiogenesis and 
lymphangiogenesis markers that might be of interest in the comparison between the unaltered psoriatic and 
healthy volunteer skin. 
Expression of the selected mRNAs in psoriasis lesions and in nonlesional skin 
The amount of total RNA extracted from the punch biopsies of psoriasis lesions was on average 3
.
2 higher than 
the quantity recovered from nonlesional psoriatic and healthy skin biopsies of similar diameter, in agreement 
with the hypercellularity and the rRNA amounts measured in cryosections as described above. The results 
expressed in arbitrary units per unit of 28S rRNA represent a measure of the specific mRNA on a per cell basis. 
Our data are consistent with previous studies
27
 as keratin 16, synthesized by proliferating epidermal cells, keratin 
14, expressed by dividing basal cells, collagen IV, a basement membrane collagen, and the proliferation marker 
proliferating cell nuclear antigen (PCNA) were overexpressed in the lesions, while the reduced expression of 
vimentin per unit of 28S also observed in the lesions is likely to be related to the dilution of RNA from dermal 
cells (Table 1). No significant difference existed in the expression of keratin 10, collagen I, VEGF121, 
VEGF165 and VEGF189, when expressed per cell unit. Only the PlGF-1 and PlGF-2 isoforms were observed in 
our samples. These factors were both overexpressed in the lesions as compared with the distant uninvolved skin, 
while the expression of the antiangiogenic factor semaphorin 3A, a VEGF competitor and antagonist that binds 
to neuropilin-1 (NRP-1)
25
, was reduced.  Neuropilin-2a (NRP-2a), that acts as a coreceptor for VEGF-A and 
VEGF-C by interacting with VEGFR2 and VEGFR3,
28-31
 was also increased in lesions, while VEGF-D mRNA 
expression was reduced. The mRNAs of other lymph-angiogenic markers were not modified. 
 
Fig 3: Electrophoretic pattern of the amplified products of selected genes. RNA was extracted from punch biopsies of 
uninvolved (NP) and involved (LP) skin of patients with psoriasis and from healthy volunteer skin (NV). Reverse transcription—polymerase 
chain reaction (RT-PCR) was performed in duplicate for 28S, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), vascular endothelial 
growth factor (VEGF)-A and VEGFR3. The efficiency of the RT and PCR reactions for 28S, GAPDH and VEGF-A was controlled by an 
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Epidermal and dermal markers expression in nonlesional psoriatic and healthy volunteer skin 
As shown in Table 2, the expression of keratin 10, keratin 14 and keratin 16, vimentin, collagen I, collagen IV 
and PCNA was similar in both groups, in agreement with morphological and proliferative features. By contrast, 
GAPDH mRNA was significantly increased in the nonlesional skin in psoriasis as compared with the healthy 
skin (Fig. 4). 
 
Table 1: Expression of general, angiogenesis and lymphangiogenesis markers in the uninvolved and lesional 
skin of patients with psoriasis 
RNA Uninvolved skin Lesional skin 
General markers   
   Epidermal   
      Keratin 10 817 ± 219 732 ± 202 
      Keratin 16 264 ± 350 4042 ± 4999 
      Keratin 14 228 ± 112 541 ± 798 
   Dermal   
      Collagen I 245 ± 170 218 ± 149 
      Vimentin 367 ± 100 285 ± 130 
   Basement membrane   
      Collagen IV 194 ± 98 452 ± 325 
   Proliferation   
      PCNA 153 ± 181 418 ± 390 
   Metabolism   
      GAPDH 216 ± 55 250 ± 117 
Angiogenesis   
   Ligands   
      VEGF121 238 ± 104 246 ± 133 
      VEGF165 59 ± 40 60 ± 30 
      VEGF189 15 ± 9 18 ± 12 
      PlGF-1 193 ± 93 518 ± 606 
      PlGF-2 561 ± 319 1609 ± 1997 
      Semaphorin 3A 283 ± 190 227 ± 170 
   Receptors   
      VEGFR1 226 ± 130 190 ± 50 
      VEGFR2 113 ± 44 104 ± 43 
      sVEGFR1 273 ± 104 311 ± 83 
   Coreceptors   
      NRP-1 477 ± 141 407 ± 115 
      s11NRP-1 109 ± 56 113 ± 74 
      s12NRP-1 160 ± 59 201 ± 90 
Lymphangiogenesis   
   Ligands   
      VEGF-C 141 ± 84 118 ± 59 
      VEGF-D 30 ± 26 15 ± 10 
   Receptor   
      VEGFR3 33 ± 19 24 ± 19 
   Coreceptor   
      NRP-2a 35 ± 29 107 ± 150 
   Transcription factor   
      Prox-1 183 ± 81 185 ± 72 
Results are shown as mean ± SD. The values are expressed in arbitrary units of mRNA per unit of 28S rRNA. PCNA, proliferating cell 
nuclear antigen; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; VEGF, vascular endothelial growth factor; PlGF, placental growth 
factor; NRP, neuropilin. 
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Expression of angiogenesis-related markers in nonlesional psoriatic and healthy volunteer skin 
Ligands 
As shown in Table 3, the VEGF121, VEGF165 and VEGF189 isoforms were expressed in all samples while 
VEGF111 was not detected. The VEGF121 mRNA level was significantly increased in nonlesional psoriatic skin 
as compared with healthy volunteer skin (Fig. 4) while the two other VEGF isoforms, PlGF-1, PlGF-2 and 
semaphorin 3A were expressed at a similar level. 
Receptors and coreceptors 
No difference was observed in the expression levels of VEGFR1, of its soluble antagonist form sVEGFR1 and of 
VEGFR2. NRP-1 is a coreceptor that binds and presents VEGF165 to VEGFR2, enhancing its biological 
activity
8
. Two soluble NRP-1 (sNRP-1) isoforms generated by pre-mRNA processing of intron 12 (s12NRP-l) 
and intron 11 (s11NRP-1) have been described as VEGF165 antagonists.
32,33
 The soluble neuropilin s12NRP-1 
was significantly increased in uninvolved psoriatic skin as compared with healthy individuals (Fig. 4) while no 
significant difference was observed for NRP-1 and s11NRP-1. 
Expression of lymphangiogenesis-related markers in nonlesional psoriatic and healthy volunteer skin 
Ligands, receptor and coreceptor 
As shown in Table 4, the mRNA level of the lymphangiogenesis receptor VEGFR3 was significantly increased 
in the nonlesional psoriatic skin as compared with healthy volunteer skin (Fig. 4) whereas the lymphatic 
endothelial cell growth factors VEGF-C and VEGF-D displayed the same level. The mRNA of NRP-2a tended 
to be higher in uninvolved psoriatic skin (P = 0
.
08). The other isoform of NRP-2, NRP-2b, and its soluble form, 
s9NRP-2
33
, were not detected in our skin samples. 
Differentiation marker 
Prox-1 is a homeotic protein that specifies the lymphatic cell fate by reprogramming the transcriptome of 
embryonic venous endothelial cells
30
. Prox-1 mRNA expression tended to be increased in uninvolved psoriatic 
skin (P = 0
.
052) and correlated positively with that of NRP-2a (P = 0
.
02, not illustrated). 
 
Table 2: Expression of epidermal, dermal and metabolic markers in skin from healthy volunteers and 
uninvolved skin from patients with psoriasis 
Markers Healthy skin Uninvolved skin 
Epidermal   
      Keratin 10 100 ± 37 121 ± 32 
      Keratin 16 100 ± 130 233 ± 309 
      Keratin 14 100 ± 48 181 ± 89 
Dermal   
      Collagen I 100 ± 89 155 ± 107 
      Vimentin 100 ± 56 129 ± 35 
Basement membrane   
      Collagen IV 100 ± 78 115 ± 58 
Proliferation   
      PCNA 100 ± 105 82 ± 97 
Metabolism   
      GAPDH 100 ± 43 162 ± 41
a
 
Results are shown as mean ± SD percentage of the value measured in healthy volunteers taken as 100%. aSignificant statistical difference 
between uninvolved psoriatic skin (n = 13) and healthy skin (n = 16) (P < 0.05), ANOVA and Scheffé's test. PCNA, proliferating cell nuclear 
antigen; GAPDH, glyceraldehyde-3-phosphate dehydrogenase. 
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Fig 4: GAPDH, VEGF121, s12NRP-1 and VEGFR3 mRNA expression values (mean ± SD percentage of the 
value measured in healthy volunteers taken as 100%) in healthy volunteers (NV; black) and uninvolved psoriasis 
skin (NP; grey) groups (*P < 0
.
05). GAPDH, glyceraldehyde-3-phosphate dehydrogenase; VEGF, vascular 
endothelial growth factor; NRP, neuropilin. 
 
 
Table 3: Expression of angiogenesis related markers in skin from healthy volunteers and uninvolved skin from 
patients with psoriasis 
Markers Healthy skin Uninvolved skin 
Ligands   
      VEGF121 100 ± 35 168 ± 73
a
 
      VEGF165 100 ± 45 133 ± 90 
      VEGF189 100 ± 161 123 ± 73 
      PlGF-1 100 ± 49 117 ± 56 
      PlGF-2 100 ± 46 111 ± 63 
      Semaphorin 3A 100 ± 62 135 ± 91 
Receptors   
      VEGFR1 100 ± 65 123 ± 70 
      VEGFR2 100 ± 51 149 ± 58 
      sVEGFR1 100 ± 39 104 ± 40 
Coreceptors   
      NRP-1 100 ± 39 103 ± 29 
      s1 1NRP-1 100 ± 64 195 ± 100 
      s1 2NRP-1 100 ± 80 173 ± 63
a
 
Results are shown as mean ± SD percentage of the value measured in healthy volunteers taken as 100%. Significant statistical difference 
between uninvolved psoriatic skin (n = 13) and healthy skin (n = 16) (P < 0.05), ANOVA and Scheffé's test. VEGF, vascular endothelial 
growth factor; PlGF, placental growth factor; NRP, neuropilin. 
 
Table 4: Expression of lymphangiogenesis markers in skin from healthy volunteers and uninvolved skin from 
patients with psoriasis 
Markers Healthy skin Uninvolved skin 
Ligands   
      VEGF-C 100 ± 40 109 ± 65 
      VEGF-D 100 ± 66 169 ± 148 
Receptor   
      VEGFR3 100 ± 55 233 ± 134
a
 
Coreceptor   
      NRP-2a 100 ± 54 148 ± 127 
Differentiation   
      Prox-1 100 ± 50 136 ± 60 
Results are shown as mean ± SD percentage of the value measured in healthy volunteers taken as 100%. Significant statistical difference 
between uninvolved psoriatic skin (n = 13) and healthy skin (n = 16) (P < 0.05), ANOVA and Scheffé's test. VEGF, vascular endothelial 
growth factor; NRP, neuropilin. 
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With nine susceptibility loci already described, the predisposition to psoriasis probably results from a 
combination of inherited genes that interact. This has led us to search for alterations in the expression of genes 
related to angiogenesis and lymphangiogenesis in the uninvolved skin of patients with psoriasis. 
In agreement with recent data,
34,35
 blood and lymphatic vessel density was similar in uninvolved psoriatic skin 
and in skin of normal volunteers. The same conclusions were reached for the other morphological parameters 
and the expression of epidermal, dermal and proliferative markers, indicating a comparable biosynthetic activity 
and supporting the absence of subclinical psoriasis lesions in the biopsies collected at distance. The increased 
expression of GAPDH in the psoriasis group, however, suggests the existence of an increased mitochondrial 
activity not only in the lesions, as we and others found,
36
 but also in uninvolved skin. Our morphological 
investigations also demonstrate that the lymphatic capillaries are not only more abundant in the superficial 
dermis in the lesions when compared with the uninvolved tegument but are also significantly closer to the 
epidermis. 
By using discriminant analysis on the angiogenesis markers, the best variable to discriminate the nonlesional and 
normal volunteers groups was VEGF121 which was overexpressed in the uninvolved psoriatic skin. Focal over-
expression of VEGF-A mRNA was previously detected by in situ hybridization
7
 in the nonlesional skin in 
psoriasis. However, the isoform was not identified and microscopic abnormalities were suggestive of early 
psoriasis activity. Our results indicate that the uninvolved psoriatic skin displays either an increased VEGF121 
transcription, and/or stability of the transcript and/or regulated alternative splicing. This freely diffusible form 
could be responsible for the increased vascular permeability described in this group
18
 and therefore could 
promote an abnormal inflammatory response for minor trauma (Köbner phenomenon). This is also in agreement 
with previous observations showing that the VEGF gene, located on chromosome 6p21 relatively close to the 
PSORS1 locus,
37
 is polymorphic and that a single polymorphism in the untranslated region of the gene is 
associated with psoriasis type I
38
. The absence of any significant alteration of VEGF expression in the lesions 
when compared with the nonlesional skin in the same patients, as we observed in our study, is related to the 
normalization by 28S rRNA that gives an estimation of mRNA value per cell unit, suggesting a similar level of 
expression of VEGF per cell. The overall increase of VEGF mRNA in psoriatic lesions
7
 could therefore be 
related to the increased cellularity. We indeed measured a higher expression of the different isoforms of VEGF-
A, as well as of VEGFR2, VEGF-C, VEGFR3 and prox-1 in lesional skin as compared with nonlesional in a 
series of 10 patients with psoriasis when the mRNAs levels were expressed by unit volume (µm
3
) of tissue 
instead of 28S rRNA (data not shown). 
The increased expression of the soluble s12NRP-1 in the uninvolved skin of patients with psoriasis might 
interfere with the binding of VEGF-A to its receptor VEGFR2 and offers a counterbalance to its angiogenic 
effects. sNRP targeted to the skin is indeed able to inhibit vascular permeability
39
. In the lesions, the reduced 
expression of semaphorin 3A coupled to the overexpression of PlGF-1 and PlGF-2 could promote angiogenesis. 
Among lymphangiogenesis markers, the best variable enabling discrimination between nonlesional psoriasis and 
healthy volunteer skin was VEGFR3. The similar lymphatic vessel density in those groups might indicate that 
the production of VEGFR3 mRNA per lymphatic endothelial cell is increased in uninvolved psoriatic skin. The 
increased number of lymphatic vessels seen in the psoriasis lesions might be related to the overexpression of 
NRP-2a, which has a crucial role in endothelial cell survival and migration, and could represent a mechanism 
leading to an increased number of lymphatic vessels by promotion of VEGFR3 activity. Recent work suggests 
that keratinocytes express VEGFR3 and NRP-2 in vitro and in vivo
40
, and could be another potential source for 
these factors. 
The present study provides additional evidence that the distant uninvolved skin in psoriasis presents vascular and 
lymphatic transcriptomic differences when compared with healthy skin without major modification in the 
expression of epidermal or dermal genes. This is consistent with the fact that the characteristic vascular features 
of psoriasis are among the first phenotypic variations observed in the genesis of a lesion. It adds evidence for a 
predisposition to inflammatory and vascular over-responsiveness to unspecified stimuli in the disease. 
Alterations in the expression of those mRNAs in clinically uninvolved skin distant from active plaques could 
result from genetically determined alterations in their transcription but could also be triggered by factors 
(cytokines) released by the active lesion. Whether the corresponding proteins are increased or not is under 
investigation. Whatever the issue, the post-transcriptional/ translational mechanisms regulating their expression 
are worthy of investigation and are at the centre of our future interests. 
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